Antoni Ribas

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Immunotherapy of hepatocellular carcinoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Expert Opin Biol Ther 2:123-33. 2002
  2. pmc Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
    Mohammad Atefi
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e28973. 2011
  3. ncbi request reprint Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Amanda Lassen
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 13:83. 2014
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
  5. pmc Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
    Giusy Gentilcore
    Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    BMC Cancer 13:17. 2013
  6. pmc Combining cancer immunotherapy and targeted therapy
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, United States
    Curr Opin Immunol 25:291-6. 2013
  7. pmc Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    J Transl Med 10:236. 2012
  8. doi request reprint Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Ave, Los Angeles, CA 90095 1782, USA
    J Clin Oncol 31:616-22. 2013
  9. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
  10. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011

Research Grants

Detail Information

Publications89

  1. ncbi request reprint Immunotherapy of hepatocellular carcinoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Expert Opin Biol Ther 2:123-33. 2002
    ..The most recent data supporting the use of immunotherapy for hepatocellular cancer is reviewed in detail...
  2. pmc Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
    Mohammad Atefi
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e28973. 2011
    ..Clinical trials are in progress using MEK inhibitors following disease progression in patients receiving BRAF inhibitors. However, the PI3K/AKT pathway can also induce resistance to the inhibitors of MAPK pathway...
  3. ncbi request reprint Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Amanda Lassen
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 13:83. 2014
    ..In this study we investigated whether co-targeting the MAPK and the PI3K-AKT pathway can prevent emergence of resistance or provide additional growth inhibitory effects in vitro...
  4. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012"
    Paolo A Ascierto
    Istituto Nazionale Tumori, Fondazione G, Pascale, Naples, Italy
    J Transl Med 11:137. 2013
    ....
  5. pmc Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
    Giusy Gentilcore
    Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    BMC Cancer 13:17. 2013
    ..We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations...
  6. pmc Combining cancer immunotherapy and targeted therapy
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, United States
    Curr Opin Immunol 25:291-6. 2013
    ....
  7. pmc Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA 90095 1782, USA
    J Transl Med 10:236. 2012
    ..The similarly fully human anti-CTLA4 antibody tremelimumab had been developed in the clinic at a fixed rate infusion, resulting in very prolonged infusion times. A new formulation of tremelimumab allowed testing a shorter infusion time...
  8. doi request reprint Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Ave, Los Angeles, CA 90095 1782, USA
    J Clin Oncol 31:616-22. 2013
    ..This phase III study evaluated overall survival (OS) and other safety and efficacy end points in patients with advanced melanoma treated with tremelimumab or standard-of-care chemotherapy...
  9. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 10:83. 2012
    ....
  10. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  11. pmc New challenges in endpoints for drug development in advanced melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, CA90095, USA
    Clin Cancer Res 18:336-41. 2012
    ....
  12. pmc Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
    Paolo A Ascierto
    Unit of Medical Oncology and Innovative Therapies, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:196. 2011
    ....
  13. pmc Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"
    Paolo A Ascierto
    Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Transl Med 9:32. 2011
    ..Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies...
  14. pmc A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
    Lisa H Butterfield
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, 15213, USA
    J Transl Med 6:81. 2008
    ..This foreword provides an overview of the task force and invites feedback from readers that might be incorporated in the discussions and in the final document...
  15. pmc Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
    Hideaki Tahara
    Department of Surgery and Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
    J Transl Med 7:45. 2009
    ..The institution of an interactive consortium for high throughput molecular monitoring of clinical trials with voluntary participation might provide cost-effective solutions...
  16. doi request reprint Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206)
    Antoni Ribas
    Division of Hematology Oncology, 11 934 Factor Building UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, California 90095 1782, USA
    Oncologist 13:10-5. 2008
    ..A pivotal phase III trial has also completed accrual; that study compared the overall survival of previously untreated patients receiving single-agent tremelimumab versus dacarbazine or temozolomide...
  17. ncbi request reprint Cancer immunotherapy using gene-modified dendritic cells
    Antoni Ribas
    Departments of Surgery, Medicine, Division of Hematology Oncology, 11 934 Factor Bldg UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Curr Gene Ther 2:57-78. 2002
    ..These data may help in the translation of this promising approach to the clinic...
  18. doi request reprint Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:390-9. 2009
    ..In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity...
  19. pmc Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
    Antoni Ribas
    University of California Los Angeles UCLA, CA, USA
    J Transl Med 8:89. 2010
    ....
  20. doi request reprint Clinical development of the anti-CTLA-4 antibody tremelimumab
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles UCLA, Los Angeles, CA 90095 1782, USA
    Semin Oncol 37:450-4. 2010
    ....
  21. pmc Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
    ..18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood...
  22. pmc Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:6267-76. 2009
    ..The combination was tested in a phase I clinical trial in patients with advanced melanoma...
  23. doi request reprint Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial
    Antoni Ribas
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 17:2987-96. 2011
    ..The goal of this study was to test the safety and activity of a therapeutic vaccine, MKC1106-MT, in patients with metastatic melanoma...
  24. doi request reprint Do we need a different set of response assessment criteria for tumor immunotherapy?
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:7116-8. 2009
    ..In this issue of Clinical Cancer Research, Wolchok et al. attempt to address this peculiarity by proposing a new set of criteria termed immune-related response criteria...
  25. ncbi request reprint Determinant spreading and tumor responses after peptide-based cancer immunotherapy
    Antoni Ribas
    Department of Medicine, 54 140 CHS, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Trends Immunol 24:58-61. 2003
    ....
  26. doi request reprint Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, UCLA, Los Angeles, California, USA
    J Nucl Med 51:340-6. 2010
    ..However, there is a paucity of data demonstrating that lymphocyte proliferation does occur in humans treated with CTLA4-blocking antibodies...
  27. ncbi request reprint Genetically modified dendritic cells for cancer immunotherapy
    Antoni Ribas
    Division of Hematology Oncology, University of California at Los Angeles, CA 90095 1782, USA
    Curr Gene Ther 5:619-28. 2005
    ..These preliminary experiences suggest that genetically modified DC can safely induce T cell responses but few clinical responses...
  28. ncbi request reprint Clinical trials with tumor antigen genetically modified dendritic cells
    Antoni Ribas
    Department of Medicine and Surgery, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, CA 90095 1782, USA
    Semin Oncol 32:556-62. 2005
    ..However, antitumor activity has been marginal thus far. In conclusion, tumor antigen genetically modified DC are a feasible strategy to activate tumor-specific T cells in humans...
  29. ncbi request reprint Current developments in cancer vaccines and cellular immunotherapy
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, 90095 1782, USA
    J Clin Oncol 21:2415-32. 2003
    ....
  30. ncbi request reprint Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
    ..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches...
  31. ncbi request reprint Update on immunotherapy for melanoma
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles School of Medicine, 90095, USA
    J Natl Compr Canc Netw 4:687-94. 2006
    ..The higher response rates with modern immunotherapy approaches may allow exploration of the molecular mechanisms that make tumor targets sensitive or resistant to immunotherapy...
  32. ncbi request reprint Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, 90095, USA
    Cancer Immunol Immunother 55:663-71. 2006
    ..3) In sensitive targets a putative activating NK ligand in DC-stimulated NK cells from CD8alphaKO mice signals directly to PI3-K, but is distinct from NKG2D...
  33. pmc MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro
    Swagatam Ray
    Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
    Clin Immunol 136:338-47. 2010
    ..MHC class I-restricted tumor epitope specific TCR transduced CD4+ T cells, therefore, could be useful in immunotherapeutic strategies for melanoma or other human malignancies...
  34. doi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009
    ....
  35. pmc Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma
    Lisa H Butterfield
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    J Immunother 31:294-309. 2008
    ..Responses in CD8+ and CD4+ T cells to additional antigens were noted in 2 patients. The AdVMART1-transduced DC vaccine was safe and immunogenic in patients with metastatic melanoma...
  36. ncbi request reprint Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
    Antoni Ribas
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
    J Immunother 27:354-67. 2004
    ..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy...
  37. pmc Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824
    Dan D Vo
    Department of Medicine, Division of Hematology Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA
    Cancer Res 69:8693-9. 2009
    ..In conclusion, the HDAC inhibitor LAQ824 significantly enhances tumor immunotherapy through effects on target tumor cells as well as improving the antitumor activity of tumor antigen-specific lymphocytes...
  38. ncbi request reprint Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)
    Lana Y Schumacher
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles 90095, USA
    J Immunol 176:4757-65. 2006
    ..In conclusion, the proteasome inhibitor bortezomib can pharmacologically sensitize tumor cells to the lytic effects of DC-activated immune effector cells...
  39. ncbi request reprint Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses
    Lana Schumacher
    Division of Surgical Oncology, UCLA Medical Center, University of California Los Angeles, USA
    J Immunother 27:191-200. 2004
    ..This study has important implications for the design of DC-based clinical trials...
  40. ncbi request reprint Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
    Jennifer A Wargo
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Gene Ther 12:516-27. 2005
    ..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells...
  41. ncbi request reprint Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Ther 15:971-80. 2007
    ..Thus, DC precursors can be genetically engineered after a single ex vivo manipulation, resulting in DC vaccines with improved activity...
  42. ncbi request reprint Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines
    Antoni Ribas
    Department of Surgery, University of California at Los Angeles, 90095 1782, USA
    Cancer Gene Ther 9:875-83. 2002
    ..In conclusion, in this animal model, IL-12 production by gene-modified DC leads to a cytokine-induced dose-dependent inhibition of antigen-specific antitumor protection...
  43. pmc The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 16:6040-8. 2010
    ..Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of PLX4032 on immune cells were studied to explore the feasibility of future combinatorial approaches with immunotherapy for melanoma...
  44. ncbi request reprint Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma
    Lisa H Butterfield
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Clin Cancer Res 9:998-1008. 2003
    ..The purpose of this study was to determine the toxicity and immunological effects of three different doses and two routes of administration of autologous dendritic cells (DCs) pulsed with the MART-1(27-35) immunodominant epitope...
  45. ncbi request reprint Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma
    Bradley R Straatsma
    Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California 90095, USA
    Am J Ophthalmol 143:958-969. 2007
    ..To determine the ocular safety of CP-675,206 (Pfizer, New York, New York, USA), a fully human anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody in clinical trials of immunotherapy of metastatic melanoma...
  46. pmc Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    Franziska Niehr
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
    J Transl Med 9:76. 2011
    ..A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines...
  47. pmc Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
    Erika von Euw
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
    Mol Cancer 11:22. 2012
    ..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2...
  48. ncbi request reprint Immune rejection in a humanized model of murine prostate cancer
    Dorthe Schaue
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
    Anticancer Res 30:409-14. 2010
    ..Background/Aim: We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice...
  49. ncbi request reprint Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma
    Lynn K Gordon
    Department of Ophthalmology, and the Jules Stein Eye Institute, and the UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, 100 Stein Plaza, Los Angeles, CA 90095 7000, USA
    Control Clin Trials 25:400-7. 2004
    ..To report the protocol for surveillance of the eye and vision in a clinical trial of MART1-transduced dendritic cells for metastatic melanoma...
  50. pmc Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:14286-91. 2010
    ..This approach of TCR engineering and molecular imaging reporter gene labeling is directly translatable to humans and provides useful information on how to clinically develop this mode of therapy...
  51. ncbi request reprint Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology Surgery, University of California at Los Angeles, CA, USA
    J Clin Oncol 23:8968-77. 2005
    ..A phase I trial was conducted to test the safety of CP-675,206...
  52. pmc Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, David Geffen School of Medicine at UCLA, CHS 74 145, 10833 Le Conte Avenue, PO Box 956901, Los Angeles, CA 90095, USA
    Cancer Immunol Immunother 57:1279-89. 2008
    ..These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors...
  53. ncbi request reprint Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells
    Yu Pei Liao
    Department of Radiation Oncology, Division of Surgical Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 173:2462-9. 2004
    ..1/K(b) transgenic mice. Taken together, these results suggest that radiation modulates MHC class I-mediated antitumor immunity by functionally affecting DC Ag presentation pathways...
  54. doi request reprint Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma
    Swagatam Ray
    Department of Medicine, University of Connecticut Health Center, 263 Farmington Avenue, L 3080, Farmington, CT 06030, USA
    Clin Dermatol 27:603-13. 2009
    ....
  55. pmc CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans
    Rong Rong Huang
    Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Clin Cancer Res 17:4101-9. 2011
    ..A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses...
  56. pmc Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen
    Chengyi J Shu
    Department of Microbiology, Immunology and Molecular Genetics, University of California at Los Angeles, Los Angeles, CA 90095 1662, USA
    Int Immunol 21:155-65. 2009
    ..PET may have significant clinical utility by providing the means to quantify anti-tumor T cells throughout the body and provide early correlates for treatment efficacy...
  57. pmc Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    Hubing Shi
    Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
    Nat Commun 3:724. 2012
    ..Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma...
  58. pmc BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer Res 72:3928-37. 2012
    ..Taken together, our findings, derived from 2 independent models combining BRAF-targeted therapy with immunotherapy, support the testing of this therapeutic combination in patients with BRAFV600 mutant metastatic melanoma...
  59. pmc Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors
    Hubing Shi
    Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
    Cancer Discov 2:414-24. 2012
    ..Thus, activating MEK1 exon 3 mutations identified herein and concurrent with V600E/KBRAF do not cause BRAFi resistance in melanoma...
  60. pmc Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 6:22. 2008
    ..CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated...
  61. ncbi request reprint Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Cancer Immunol Immunother 56:1931-43. 2007
    ....
  62. ncbi request reprint NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain
    Robert M Prins
    Department of Surgery, Division of Neurosurgery, Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    J Immunol 177:8448-55. 2006
    ..Our results suggest that a better understanding of the cross-talk between DC and innate immune cells may provide improved methods to vaccinate patients with tumors located both systemically and within the CNS...
  63. pmc CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    Erika von Euw
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
    J Transl Med 7:35. 2009
    ..We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature...
  64. pmc The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy
    Paul C Tumeh
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, California, USA
    J Immunother 33:759-68. 2010
    ....
  65. pmc CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model
    Arvind Chhabra
    Department of Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
    J Immunol 181:1063-70. 2008
    ..Such TCR engineered CD4(+) T cells, therefore, might be useful in clinical immunotherapy...
  66. ncbi request reprint Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 12:107-16. 2006
    ..Define an immunologic response using the tetramer and enzyme-linked immunospot (ELISPOT) assays...
  67. ncbi request reprint T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer
    Lisa H Butterfield
    Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 9:5902-8. 2003
    ..We wished to test the hypothesis that AFP peptide-reactive T cells could be expanded in vivo in HCC patients immunized with these four AFP peptides...
  68. pmc Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition
    Hubing Shi
    Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Cancer Res 71:5067-74. 2011
    ..Together, our findings offer a rational strategy to guide clinical testing in preidentified subsets of patients who relapse during treatment with (V600E)B-RAF inhibitors...
  69. ncbi request reprint A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides
    Lisa H Butterfield
    Department of Medicine, Surgery and Immunology, Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 12:2817-25. 2006
    ..We conclude that the human T cell repertoire is capable of responding to the AFP self antigen after the administration of AFP peptide-pulsed DC even in an environment of high circulating levels of this oncofetal antigen...
  70. pmc Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma
    Begona Comin-Anduix
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 5:e12711. 2010
    ....
  71. pmc T-cell responses to survivin in cancer patients undergoing radiation therapy
    Dorthe Schaue
    Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California 90095 1714, USA
    Clin Cancer Res 14:4883-90. 2008
    ..The goal of this study was to determine if radiation therapy (RT) of human cancer enhances or diminishes tumor-specific T-cell reactivity. This is important if immunotherapy is to be harnessed to improve the outcome of cancer radiotherapy...
  72. pmc Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Jonas N Søndergaard
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 8:39. 2010
    ..In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity...
  73. pmc Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    Ramin Nazarian
    Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
    Nature 468:973-7. 2010
    ....
  74. pmc Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway
    Veerauo V Konkankit
    Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
    J Transl Med 9:192. 2011
    ..However, the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the implementation of targeted immune-based therapies...
  75. ncbi request reprint Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California at Los Angeles, Los Angeles, CA, USA
    Oncologist 12:873-83. 2007
    ....
  76. pmc Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells
    Dimitrios N Vatakis
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles CA 90095, USA
    Proc Natl Acad Sci U S A 108:E1408-16. 2011
    ..These studies present a potential therapeutic approach and an important tool to understand better and to optimize the human immune response to melanoma and, potentially, to other types of cancer...
  77. ncbi request reprint Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies
    Jay Soriano Dela Cruz
    Department of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles UCLA, Los Angeles, CA 90095, USA
    Mol Immunol 43:667-76. 2006
    ....
  78. pmc A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations
    Nam T Vu
    Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095 1770, USA
    J Nucl Med 52:815-21. 2011
    ..This paper demonstrates that the integrated system enables digital control and quantitative measurements of glycolysis in B-Raf(V600E)-mutated melanoma cell lines in response to specific B-Raf inhibition...
  79. pmc A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
    Chao Ma
    NanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, California, USA
    Nat Med 17:738-43. 2011
    ..The platform represents a new and informative tool for immune monitoring and clinical assessment...
  80. doi request reprint siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide
    Jonathan E Zuckerman
    Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1782, USA
    J Invest Dermatol 131:453-60. 2011
    ..In conclusion, siRNA-mediated RRM2 knockdown significantly inhibits proliferation of melanoma cell lines with different oncogenic mutations with synergistic enhancement in combination with temozolomide...
  81. doi request reprint CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893
    Anusha Kalbasi
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
    J Immunother 33:810-6. 2010
    ..Direct exposure to a CD40-activating antibody does not lead to antitumor activity in melanoma cell lines, suggesting that the antitumor effects of these antibodies in the clinic may be indirectly mediated...
  82. pmc HMGB1 mediates endogenous TLR2 activation and brain tumor regression
    James F Curtin
    Department of Medicine, Board of Governors Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS Med 6:e10. 2009
    ....
  83. doi request reprint A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma
    Evan M Hersh
    Department of Medicine, Arizona Cancer Center, Tucson, AZ 85724, USA
    Cancer 116:155-63. 2010
    ..In the current study, the efficacy and safety of nab-paclitaxel were evaluated in previously treated and chemotherapy-naive patients with metastatic melanoma (MM)...
  84. ncbi request reprint Metastatic melanoma to the kidney presenting with renal vein tumor thrombus
    Tobias Klatte
    Department of Urology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Urology 69:982.e7-9. 2007
    ..The patient later had tumor recurrence at multiple sites. He did not respond to systemic treatment and died 5 months later...
  85. ncbi request reprint Therapeutic cancer vaccines
    Lilah F Morris
    Department of Surgery, UCLA Medical Center, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Surg Oncol Clin N Am 16:819-31, ix. 2007
    ..Finally, strategies to directly expand antitumor T lymphocytes and adoptively transfer them to patients with cancer have been developed and shown to induce objective tumor regressions...
  86. doi request reprint PET imaging of cancer immunotherapy
    Paul C Tumeh
    UCLA, Los Angeles, California, USA
    J Nucl Med 49:865-8. 2008
    ..In conclusion, these novel PET-based imaging approaches have demonstrated promise toward the goal of in vivo, noninvasive immune monitoring strategies for evaluating cancer immunotherapy...
  87. ncbi request reprint [Clinical development of antitumoral vaccines]
    Antoni Ribas
    División de Hematología Oncología, Universidad de California, Los Angeles, USA
    Med Clin (Barc) 118:472-6. 2002
  88. pmc Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model
    Sumia Ali
    Molecular Medicine and Gene Therapy Unit, University of Manchester, Manchester, United Kingdom
    Cancer Res 65:7194-204. 2005
    ..We propose that combined Flt3L and HSV1-TK adenoviral-mediated gene therapy may provide an effective antiglioma treatment with increased efficacy in clinical trials of glioma...
  89. doi request reprint Targeted therapies to improve tumor immunotherapy
    Jonathan Begley
    Monash University, Victoria, Melbourne, Australia
    Clin Cancer Res 14:4385-91. 2008
    ....

Research Grants1

  1. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..